NICE Expands Guidance for Rhythm Pharmaceuticals’ IMCIVREE to Include Adults With Bardet-Biedl Syndrome

Two medical researchers examining digital DNA imagery in a laboratory, representing genetic research and treatment development for rare inherited conditions such as Bardet-Biedl syndrome.

Key Points

  • NICE issued positive guidance extending IMCIVREE reimbursement eligibility to adults with genetically confirmed Bardet-Biedl syndrome, or BBS.
  • The update enables eligible adults to access NHS-funded treatment in England, Wales and Northern Ireland.
  • The previous recommendation, issued in May 2024, focused treatment initiation on patients aged 6–17.
  • NICE considered additional clinical, real-world and longer-term treatment evidence.
  • Existing access arrangements for children aged 2–5 in England and Wales remain unchanged.

Rhythm Pharmaceuticals (NASDAQ: RYTM) has secured broader access for IMCIVREE, or setmelanotide, through updated NICE guidance.

The change extends funded treatment eligibility to adults with genetically confirmed BBS, addressing a population that continues to experience the burden of hyperphagia and obesity beyond childhood.

Updated Guidance Recognizes Lifelong Disease Burden

NICE’s assessment considered additional clinical evidence, real-world experience and longer-term treatment data, alongside the impact of BBS on patients and families.

That burden extends beyond weight and hunger to quality of life, mental health, mobility, education and independence. The updated recommendation expands on the May 2024 guidance, which had focused treatment initiation on patients aged 6–17.

The development concerns reimbursement and funded access—not a newly reported clinical trial result.

Younger Children Retain Existing Access Arrangements

Children aged 2–5 with BBS in England and Wales already have funded access through NHS England specialized commissioning arrangements.

The updated NICE guidance does not change those arrangements. The adult expansion and younger-child funding pathway should therefore be viewed as distinct access mechanisms.

Investor Takeaway: Broader Eligibility, With Uptake Still to Follow

For RYTM investors, the guidance broadens the population eligible for funded IMCIVREE treatment and supports the company’s commercialization efforts.

However, the supplied information does not quantify the number of newly eligible adults, expected treatment starts, reimbursement terms or incremental revenue. Broader eligibility creates an opportunity for additional uptake, but does not itself establish how quickly that opportunity will translate into sales.

Share this article:

About the Author:

LifeMD Expands Direct Pharmacy Access to Lilly’s Self-Pay GLP-1 Medicines

Alex Corbit

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup